Haemophilia A Prophylaxis and Bleeding Control
Research activity in haemophilia A centres on long-term prophylactic management, prevention of joint bleeds, and control of breakthrough bleeding in people with severe disease. The trials also examine treatment continuity in previously treated patients and comparative pharmacokinetics of extended half-life factor VIII products.
- Prophylactic factor VIII therapy
- Joint bleed prevention
- Bleeding episode management
- Pharmacokinetic assessment
Clinical interest extends to sustained treatment use across multiple countries and real-world settings, with a focus on maintaining protection against bleeding complications.
Joint Health and Musculoskeletal Outcomes
Several studies focus on joint health in haemophilia, including changes in physical activity, overall joint status, and structural findings such as synovial hypertrophy. Ultrasound is used to characterise joint involvement in patients receiving prophylaxis.
- Physical activity over time
- Synovial hypertrophy
- Ultrasound-based joint assessment
- Musculoskeletal function
This area reflects a strong therapeutic interest in preserving mobility and reducing haemophilia-related joint damage in both adolescents and adults.
Haemophilia B and Extended Prophylaxis
Research also includes haemophilia B, with attention to prophylactic treatment and joint outcomes in patients receiving long-acting factor IX replacement. These studies assess how ongoing prevention strategies relate to joint condition in routine care and follow-up settings.
- Factor IX prophylaxis
- Joint outcome monitoring
- Long-acting clotting factor therapy
- Haemophilia B care
The sponsor’s portfolio in this area links bleeding prevention with longer-term assessment of joint preservation in people living with inherited bleeding disorders.
Transplant-associated Thrombotic Microangiopathy
In transplant-associated thrombotic microangiopathy (TA-TMA), the research focus is on treatment evaluation after hematopoietic stem cell transplantation, with attention to pharmacokinetics, safety, and tolerability. This reflects an interest in severe post-transplant complications requiring specialised therapeutic management.
- TA-TMA treatment
- Post-transplant complications
- Safety and tolerability
- Pharmacokinetic evaluation
The sponsor’s activity in this field addresses a rare, high-acuity haematologic condition within the transplant setting.
